The Novel HLA-DRB1*03:218N Allele, Identified by Next-Generation Sequencing in a Greek Individual.

The HLA-DRB1*03:218N allele differs from HLA-DRB1*03:174N by a single nucleotide substitution in exon 2.

Identification of the Novel HLA-DQB1*05:02:01:19 Allele in a Candidate Bone Marrow Donor by Next Generation Sequencing.

The HLA-DQB1*05:02:01:19 allele differs from HLA-DQB1*05:02:01:01 by a single nucleotide substitution in intron 3.

Identification of the Novel HLA-DQB1*03:01:01:69 Allele in a Candidate Bone Marrow Donor by Next Generation Sequencing.

The HLA-DQB1*03:01:01:69 allele differs from HLA-DQB1*03:01:01:03 by a single nucleotide substitution in intron 2.

A novel HLA-DQB1*06 variant allele, HLA-DQB1*06:02:01:40, identified by next-generation sequencing.

The HLA-DQB1*06:02:01:40 allele differs from HLA-DQB1*06:02:01:01 by a single nucleotide substitution in intron 2.

A novel HLA-DQB1*03 variant allele, HLA-DQB1*03:01:01:64, identified by next-generation sequencing.

The HLA-DQB1*03:01:01:64 allele differs from HLA-DQB1*03:01:01:03 by a single nucleotide substitution in intron 2.

A novel HLA-C*07 variant allele, HLA-C*07:01:01:141, identified by next-generation sequencing.

Characterisation of the novel HLA-C*07:01:01:141 allele in a 23-year-old Greek bone marrow donor.

Erythropoietin Effect on Complement Activation in Chronic Kidney Disease.

The complement system is an important part of innate immunity. Despite its known protective role, the complement system may contribute to increased inflammation and tissue injury in cases where its balanced activation is disrupted. The kidneys have been shown to be largely affected by complement dysregulation.

Identification of the new allele HLA-A*24:632 in a Greek individual using next generation sequencing.

The HLA-Α*24:632 allele differs from HLA-A*24:02:01:01 by a single nucleotide substitution in exon 2.

Identification of the new allele HLA-C*04:01:01:186 in a Greek individual using next generation sequencing.

The newly discovered HLA-C*04:01:01:186 allele differs from HLA-C*04:01:01:01 by a single nucleotide substitution in intron 3.

The novel HLA-C*14:02:01:31 allele identified in a candidate bone marrow donor by next-generation sequencing.

Characterisation of the novel HLA-C*14:02:01:31 allele in a 21-year-old Greek bone marrow donor.

The novel HLA-C*04:01:01:182 allele identified in a candidate bone marrow donor by next-generation sequencing.

HLA-C*04:01:01:182 differs from the HLA-C*04:01:01:06 allele by one nucleotide substitution in the 5'UTR.

Characterisation of the novel HLA-B*38:01:01:18 allele by next-generation sequencing.

HLA-B*38:01:01:18 differs from the HLA-B*38:01:01:01 allele by one nucleotide substitution in the 5'UTR.

Characterisation of the novel HLA-B*07:02:01:110 allele by next-generation sequencing.

HLA-B*07:02:01:110 differs from the HLA-B*07:02:01:01 allele by two nucleotide substitutions in the 3'UTR.

A novel HLA-C*01 variant, HLA-C*01:02:01:70, identified in a healthy individual from Greece.

HLA-C*01:02:01:70 differs from the HLA-C*01:02:01:01 allele by one nucleotide substitution in the intron 4.

A novel HLA-C*04 variant, HLA-C*04:01:01:174, identified in a healthy individual from Greece.

HLA-C*04:01:01:174 differs from the HLA-C*04:01:01:06 allele by one nucleotide substitution in the intron 5.

A novel HLA-C*17 variant, HLA-C*17:01:01:29, identified in a healthy individual from Greece.

HLA-C*17:01:01:29 differs from the HLA-C*17:01:01:05 allele by one nucleotide substitution in the 3'UTR.

Discovery of the novel HLA-B*47:01:01:07 allele in a Greek volunteer bone marrow donor.

HLA-B*47:01:01:07 differs from the HLA-B*47:01:01:03 allele by one nucleotide deletion in the 3'UTR.

Discovery of the novel HLA-A*01:01:01:112 allele in a Greek volunteer bone marrow donor.

HLA-A*01:01:01:112 differs from the HLA-A*01:01:01:01 allele by one nucleotide substitution in the 5'UTR.

Genomic sequence of the novel HLA-B*41:02:01:11, and -C*08:266 alleles identified in a solid organ recipient.

HLA-B*41:02:01:11 and -C*08:266 were detected in a solid organ recipient during the HLA typing process.

Utilizing Massively Parallel Sequencing (MPS) of Human Leukocyte Antigen (HLA) Gene Polymorphism to Assess Relatedness in Deficiency Parentage Testing.

In the realm of DNA testing with legal implications, the reliability and precision of genetic markers play a pivotal role in confirming or negating paternity claims. This study aimed to assess the potential utility of human leukocyte antigen (HLA) gene polymorphism through massively parallel sequencing (MPS) technology as robust forensic markers for parentage testing involving genetic deficiencies. It sought to redefine the significance of HLA genes in this context.

Characterization of the novel HLA-A*02:01:01:243 allele by next generation sequencing in a Greek individual.

HLA-A*02:01:01:243 differs from the HLA-A*02:01:01:01 allele by one nucleotide substitution in the 5'UTR.

Characterization of the novel HLA-B*51:01:01:109 allele by next generation sequencing in a Greek individual.

HLA-B*51:01:01:109 differs from HLA-B*51:01:01:01 by one nucleotide substitution in intron 5.

Full-length sequence of the novel HLA-B*18:01:01:73 allele by next generation sequencing in a Greek individual.

HLA-B*18:01:01:73 differs from HLA-B*18:01:01:02 by one nucleotide substitution in intron 2.